| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | transcription coactivator activity | 2.00e-04 | 303 | 36 | 5 | GO:0003713 | |
| GeneOntologyMolecularFunction | histone H3 kinase activity | 2.06e-04 | 12 | 36 | 2 | GO:0140996 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | MEPCE SOX17 CITED2 NKX2-3 GTF2A1 CTBP2 TNKS DCAF6 USF3 RPS6KA4 MLLT10 FOXJ3 | 2.29e-06 | 1390 | 36 | 12 | GO:0045944 |
| Domain | TF_fork_head_CS_2 | 2.98e-03 | 46 | 33 | 2 | IPR030456 | |
| Domain | TF_fork_head_CS_1 | 3.11e-03 | 47 | 33 | 2 | IPR018122 | |
| Domain | FORK_HEAD_3 | 3.38e-03 | 49 | 33 | 2 | PS50039 | |
| Domain | FH | 3.38e-03 | 49 | 33 | 2 | SM00339 | |
| Domain | FORK_HEAD_1 | 3.38e-03 | 49 | 33 | 2 | PS00657 | |
| Domain | FORK_HEAD_2 | 3.38e-03 | 49 | 33 | 2 | PS00658 | |
| Domain | Forkhead | 3.38e-03 | 49 | 33 | 2 | PF00250 | |
| Domain | Fork_head_dom | 3.38e-03 | 49 | 33 | 2 | IPR001766 | |
| Domain | Channel_four-helix_dom | 4.55e-03 | 57 | 33 | 2 | IPR027359 | |
| Domain | - | 4.55e-03 | 57 | 33 | 2 | 1.20.120.350 | |
| Domain | Kinase-like_dom | 1.47e-02 | 542 | 33 | 4 | IPR011009 | |
| Domain | Ion_trans_dom | 1.72e-02 | 114 | 33 | 2 | IPR005821 | |
| Domain | Ion_trans | 1.72e-02 | 114 | 33 | 2 | PF00520 | |
| Pathway | WP_MESODERMAL_COMMITMENT_PATHWAY | 6.29e-06 | 153 | 25 | 5 | M39546 | |
| Pathway | REACTOME_SIGNALING_BY_WNT | 5.41e-05 | 239 | 25 | 5 | MM14756 | |
| Pathway | WP_ENDODERM_DIFFERENTIATION | 1.09e-04 | 143 | 25 | 4 | M39591 | |
| Pathway | REACTOME_SIGNALING_BY_WNT | 2.46e-04 | 330 | 25 | 5 | M7847 | |
| Pathway | WP_NCRNAS_INVOLVED_IN_WNT_SIGNALING_IN_HEPATOCELLULAR_CARCINOMA | 5.06e-04 | 89 | 25 | 3 | M39563 | |
| Pathway | WNT_SIGNALING | 5.06e-04 | 89 | 25 | 3 | M5493 | |
| Pathway | WP_LNCRNA_IN_CANONICAL_WNT_SIGNALING_AND_COLORECTAL_CANCER | 6.71e-04 | 98 | 25 | 3 | M39731 | |
| Pathway | WP_WNT_SIGNALING_PATHWAY | 9.38e-04 | 110 | 25 | 3 | MM15977 | |
| Pathway | WP_WNT_SIGNALING_WP428 | 1.01e-03 | 113 | 25 | 3 | M39669 | |
| Pathway | REACTOME_SIGNALING_BY_WNT_IN_CANCER | 1.64e-03 | 34 | 25 | 2 | M27405 | |
| Pubmed | The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. | MEPCE CITED2 DYRK1A GTF2A1 TNKS SLC39A10 ZNF281 AMOT FOXG1 NLK | 2.64e-07 | 1203 | 36 | 10 | 29180619 |
| Pubmed | The protein interaction landscape of the human CMGC kinase group. | 6.23e-06 | 695 | 36 | 7 | 23602568 | |
| Pubmed | 7.10e-06 | 36 | 36 | 3 | 27606604 | ||
| Pubmed | 1.31e-05 | 44 | 36 | 3 | 27505670 | ||
| Pubmed | 1.85e-05 | 152 | 36 | 4 | 16009940 | ||
| Pubmed | 2.87e-05 | 57 | 36 | 3 | 21122108 | ||
| Pubmed | Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). | 2.91e-05 | 8 | 36 | 2 | 20203130 | |
| Pubmed | The protein network surrounding the human telomere repeat binding factors TRF1, TRF2, and POT1. | 5.10e-05 | 197 | 36 | 4 | 20811636 | |
| Pubmed | 5.70e-05 | 11 | 36 | 2 | 11846474 | ||
| Pubmed | 8.13e-05 | 709 | 36 | 6 | 22988430 | ||
| Pubmed | 9.41e-05 | 14 | 36 | 2 | 24327562 | ||
| Pubmed | Roles of ErbB3-binding protein 1 (EBP1) in embryonic development and gene-silencing control. | 1.08e-04 | 15 | 36 | 2 | 31748268 | |
| Pubmed | 1.12e-04 | 90 | 36 | 3 | 19515997 | ||
| Pubmed | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. | 1.15e-04 | 1489 | 36 | 8 | 28611215 | |
| Pubmed | Proteostasis is essential during cochlear development for neuron survival and hair cell polarity. | 1.76e-04 | 19 | 36 | 2 | 31321879 | |
| Pubmed | 1.76e-04 | 19 | 36 | 2 | 35177595 | ||
| Pubmed | Embryo model completes gastrulation to neurulation and organogenesis. | 2.38e-04 | 22 | 36 | 2 | 36007540 | |
| Pubmed | 2.38e-04 | 22 | 36 | 2 | 27521426 | ||
| Pubmed | 2.38e-04 | 116 | 36 | 3 | 30804394 | ||
| Pubmed | A census of human transcription factors: function, expression and evolution. | 3.11e-04 | 908 | 36 | 6 | 19274049 | |
| Pubmed | 3.60e-04 | 27 | 36 | 2 | 18838386 | ||
| Pubmed | The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function. | 3.60e-04 | 27 | 36 | 2 | 28007894 | |
| Pubmed | Proteomic analysis and identification of cellular interactors of the giant ubiquitin ligase HERC2. | 4.05e-04 | 139 | 36 | 3 | 25476789 | |
| Pubmed | 4.08e-04 | 339 | 36 | 4 | 30415952 | ||
| Pubmed | Correct patterning of the primitive streak requires the anterior visceral endoderm. | 4.45e-04 | 30 | 36 | 2 | 21445260 | |
| Pubmed | 4.75e-04 | 31 | 36 | 2 | 23332764 | ||
| Pubmed | 5.26e-04 | 152 | 36 | 3 | 38360978 | ||
| Pubmed | Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae. | 5.72e-04 | 34 | 36 | 2 | 19197348 | |
| Pubmed | Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors. | 6.25e-04 | 1451 | 36 | 7 | 30550785 | |
| Pubmed | 7.91e-04 | 1084 | 36 | 6 | 11544199 | ||
| Pubmed | Regulation of epidermal differentiation through KDF1-mediated deubiquitination of IKKα. | 8.86e-04 | 182 | 36 | 3 | 32239614 | |
| Pubmed | 9.59e-04 | 44 | 36 | 2 | 30146317 | ||
| Pubmed | Proteome-scale mapping of binding sites in the unstructured regions of the human proteome. | 9.93e-04 | 430 | 36 | 4 | 35044719 | |
| Interaction | CNOT9 interactions | 2.61e-06 | 231 | 35 | 6 | int:CNOT9 | |
| Interaction | EGLN3 interactions | CITED2 DYRK1A CTBP2 PRR14L SLC39A10 PIPSL ZNF281 BIRC6 UBAP2L AMOT CPEB4 | 7.40e-06 | 1296 | 35 | 11 | int:EGLN3 |
| Interaction | RNF4 interactions | MEPCE CITED2 DYRK1A GTF2A1 TNKS SLC39A10 ZNF281 BIRC6 AMOT FOXG1 NLK | 1.67e-05 | 1412 | 35 | 11 | int:RNF4 |
| Interaction | CNOT3 interactions | 2.75e-05 | 207 | 35 | 5 | int:CNOT3 | |
| Interaction | RTRAF interactions | 3.84e-05 | 222 | 35 | 5 | int:RTRAF | |
| Interaction | CNOT11 interactions | 4.14e-05 | 112 | 35 | 4 | int:CNOT11 | |
| Interaction | JCAD interactions | 5.26e-05 | 42 | 35 | 3 | int:JCAD | |
| Interaction | THAP11 interactions | 5.79e-05 | 122 | 35 | 4 | int:THAP11 | |
| Interaction | FOXO3 interactions | 6.17e-05 | 124 | 35 | 4 | int:FOXO3 | |
| Interaction | AKAP7 interactions | 8.37e-05 | 49 | 35 | 3 | int:AKAP7 | |
| GeneFamily | Forkhead boxes | 1.24e-03 | 43 | 22 | 2 | 508 | |
| Coexpression | DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN | 4.80e-06 | 504 | 36 | 7 | M2157 | |
| ToppCell | TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5|TCGA-Ovary / Sample_Type by Project: Shred V9 | 2.21e-07 | 166 | 36 | 5 | 32d2eaf8a5d03881bf74d680825af2d5110b082d | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-hematologic-hematopoietic_progenitor-hematopoietic_stem_cell|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.27e-06 | 149 | 36 | 4 | e99b7cd3728ce76b365526734c2e7f845b2e62c8 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-hematologic-hematopoietic_progenitor|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.27e-06 | 149 | 36 | 4 | 6a28dd4530ed411747fdfe743db138a1b5547ed7 | |
| ToppCell | BAL-Severe-cDC_3|Severe / Compartment, Disease Groups and Clusters | 1.24e-05 | 177 | 36 | 4 | 939487a05311b66edfc3f44a7955fbf25266d6bf | |
| ToppCell | PBMC-Mild-Hematopoietic-HSPC|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.29e-05 | 179 | 36 | 4 | 2f690f933bf6b99abeb31766e0b22bdbe36c1ba0 | |
| ToppCell | PBMC-Mild-Hematopoietic-HSPC-HSPC-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.29e-05 | 179 | 36 | 4 | 4bb2debfc9e9f258cd38e797ef160bd440aad6af | |
| ToppCell | PBMC-Mild-Hematopoietic-HSPC-HSPC|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.29e-05 | 179 | 36 | 4 | 3e2c937369b8190fd5d5a31689d029e6e89fb5e2 | |
| ToppCell | PBMC-Mild-Hematopoietic-HSPC-HSPC|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.35e-05 | 181 | 36 | 4 | 54a19cf6a3b752e2391feb8b316bebee0e602d17 | |
| ToppCell | PBMC-Mild-Hematopoietic-HSPC|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.35e-05 | 181 | 36 | 4 | 5b84625b1d3737708001b64f6da9360330d39a27 | |
| ToppCell | PBMC-Mild-Hematopoietic-HSPC-HSPC-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.35e-05 | 181 | 36 | 4 | e7f7b519c2a01c15f26df11ec9b434c0d1630c7a | |
| ToppCell | normal-na-Hematopoietic-progenitor_cell|normal / PBMC cell types (v2) per disease, treatment status, and sex | 1.57e-05 | 188 | 36 | 4 | 013162466a3334b6967c0cb670c8577d809b1396 | |
| ToppCell | normal-na-Hematopoietic-progenitor_cell-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 1.57e-05 | 188 | 36 | 4 | be25371e6459504b5f0c9ece3a0fe8f80c7824ca | |
| ToppCell | LPS-IL1RA-Myeloid-Monocytes,_Macrophages-Erythroid|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.12e-04 | 144 | 36 | 3 | 7c471e332f87d60f4dbed01f3e66bf39995218d0 | |
| ToppCell | 10x_3'_v3-blood_(10x_3'_v3)-myeloid-myeloid_dendritic-CD141-positive_myeloid_dendritic_cell|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.79e-04 | 158 | 36 | 3 | 4f3ea658e032555c2098d016475381c8d1071699 | |
| ToppCell | wk_20-22-Hematologic-Myeloid-HSC/ELP|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 3.11e-04 | 164 | 36 | 3 | 3c07d8f53511f269540bf032738a4ada35650b18 | |
| ToppCell | wk_15-18-Hematologic-Meg-ery-HMOX1+_primitive_erythroblast|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 3.16e-04 | 165 | 36 | 3 | a040d18e4ba6da266440ad0b79990918770bfa7d | |
| ToppCell | facs-Spleen-nan-18m-Hematologic-proerythroblast|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.22e-04 | 166 | 36 | 3 | 8d535fab019356894b4dad3fbdbc4d2ad3e16082 | |
| ToppCell | facs-Spleen-nan-18m-Hematologic-nan|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.22e-04 | 166 | 36 | 3 | f56b1c0d6cb5353a16a2598bda905287f16d2c39 | |
| ToppCell | facs-Spleen-nan-18m-Hematologic|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.22e-04 | 166 | 36 | 3 | a5074c96c6561273029aceb93402a7e038140f50 | |
| ToppCell | Healthy_donor-HSPC|World / disease group, cell group and cell class (v2) | 3.28e-04 | 167 | 36 | 3 | 70630ebdfee8171d625811844f8a7c94736d101e | |
| ToppCell | facs-Skin-Anagen-24m-Epithelial-bulge_keratinocyte|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.28e-04 | 167 | 36 | 3 | 78909f685ccd1321064eb0887caf9263e0e54879 | |
| ToppCell | E17.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 3.45e-04 | 170 | 36 | 3 | 7fa022471e14ac8a3bc147c793368a4d56a8e591 | |
| ToppCell | droplet-Heart-HEART_(LV+RV_ONLY)-30m-Myeloid-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.45e-04 | 170 | 36 | 3 | f3d5678669dcaed1836014cea543758b7ccc6b46 | |
| ToppCell | Healthy_donor-HSPC|Healthy_donor / disease group, cell group and cell class (v2) | 3.57e-04 | 172 | 36 | 3 | bc7549faadfc92c683c0e26bea380458706774b5 | |
| ToppCell | facs|World / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.57e-04 | 172 | 36 | 3 | a2d0a64ebf09d219a07d6bbad1056bad6d46b9be | |
| ToppCell | severe_COVID-19-HSPC|severe_COVID-19 / disease group, cell group and cell class (v2) | 3.70e-04 | 174 | 36 | 3 | 6d35bacf073537b272ff821e604c899fb9ce6a7c | |
| ToppCell | LPS-IL1RA-Hematopoietic_Meg-Ery-Erythroid|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.76e-04 | 175 | 36 | 3 | 4d36da7399c62c170cb603957b35a35efb2c3fbe | |
| ToppCell | LPS-IL1RA-Hematopoietic_Meg-Ery|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.76e-04 | 175 | 36 | 3 | 2c39c1b112e873403ad2add8595cc256bf0b97a6 | |
| ToppCell | facs-Skin-Anagen-24m-Epithelial-outer_bulge|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.76e-04 | 175 | 36 | 3 | 5552ff1e13f931c8cd7780726c90b5609497a648 | |
| ToppCell | P15-Endothelial-lymphatic_endothelial_cell-endothelial_cell_of_lymphatic_vessel|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 3.76e-04 | 175 | 36 | 3 | 84d252f3e432231687613299bbea14978bb4b06b | |
| ToppCell | LPS-IL1RA-Hematopoietic_Meg-Ery-Erythroid-Erythroid|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.76e-04 | 175 | 36 | 3 | e4c9b3c6bde390a3892b112b673f93e118220eb9 | |
| ToppCell | P15-Endothelial-lymphatic_endothelial_cell|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 3.76e-04 | 175 | 36 | 3 | a00c6fa9b33640710dd05a3799031147196f0986 | |
| ToppCell | 10x5'v1-week_17-19-Myeloid_macrophage-stroma-erythroid_macrophage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.88e-04 | 177 | 36 | 3 | b647667da62a91dbe3890820142626e26aa779d2 | |
| ToppCell | severe_COVID-19-HSPC|World / disease group, cell group and cell class (v2) | 3.88e-04 | 177 | 36 | 3 | 289f6aed6f054b04b01659434d8c8b467d1bf5dd | |
| ToppCell | LPS-IL1RA+antiTNF-Hematopoietic_Meg-Ery|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.01e-04 | 179 | 36 | 3 | 7329b45376a9e9a4fe34d4aa0b33af6dda0a8e3b | |
| ToppCell | COVID-19_Mild-Hematopoietic_SC-HSPC|COVID-19_Mild / Disease group, lineage and cell class | 4.01e-04 | 179 | 36 | 3 | 19fcf48f5e02e4cb2b328efb4502f337e1282f72 | |
| ToppCell | LPS-IL1RA+antiTNF-Hematopoietic_Meg-Ery-Erythroid|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.01e-04 | 179 | 36 | 3 | 6e4740f99f66d3e9348fa5057cf1030454819aa8 | |
| ToppCell | COVID-19_Mild-Hematopoietic_SC|COVID-19_Mild / Disease group, lineage and cell class | 4.01e-04 | 179 | 36 | 3 | 50a073166e34bcfa52a62c4dafb3aef724e0fa8e | |
| ToppCell | LPS-IL1RA+antiTNF-Hematopoietic_Meg-Ery-Erythroid-Erythroid|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.01e-04 | 179 | 36 | 3 | ee60ac43fb62c09967a26bbcf9306ac5ea2bdc1e | |
| ToppCell | MatrixFB-Fibroblast-A|MatrixFB / shred on cell class and cell subclass (v4) | 4.08e-04 | 180 | 36 | 3 | adc64ad6033af705dd7b9163a83e20ef5c59f6eb | |
| ToppCell | PBMC-Control-Hematopoietic-HSPC-HSPC-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.21e-04 | 182 | 36 | 3 | 6497eeafb2b137e70261ec0314782831892a940d | |
| ToppCell | Control-Hematopoietic_SC-HSPC|Control / Disease group, lineage and cell class | 4.21e-04 | 182 | 36 | 3 | 14e347c0e6444410f1948851407bb18c706569f4 | |
| ToppCell | Control-Hematopoietic_SC|Control / Disease group, lineage and cell class | 4.21e-04 | 182 | 36 | 3 | 43243c6bae2ac7fa3fd1f193a17f61ee4d938ea9 | |
| ToppCell | PBMC-Control-Hematopoietic-HSPC-HSPC|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.21e-04 | 182 | 36 | 3 | d0ebf2f0d5370458ab81485a0017c311077133d5 | |
| ToppCell | PBMC-Control-Hematopoietic-HSPC|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.21e-04 | 182 | 36 | 3 | 918286422b3eab32d962b49aa07b1b9512e51d9d | |
| ToppCell | PBMC-Control-Hematopoietic-HSPC|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.21e-04 | 182 | 36 | 3 | bd1626261803324084fafca2f6665b50854e7fae | |
| ToppCell | PBMC-Control-Hematopoietic-HSPC-HSPC-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.21e-04 | 182 | 36 | 3 | 2a6d1246bfb5899a0861c7f2f8fb9b43b0df8acc | |
| ToppCell | PBMC-Control-Hematopoietic-HSPC-HSPC|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.21e-04 | 182 | 36 | 3 | 0d9b8c900da8cbae9cde72aecd4026b1ac2bbd67 | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Stem-like-NPC-like-NPC-like_neural-A|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 4.28e-04 | 183 | 36 | 3 | af14da45267261e775dd6dab7a4c359b181e46f1 | |
| ToppCell | facs-Lung-Endomucin-3m-Endothelial-Capillary_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.28e-04 | 183 | 36 | 3 | 1e51aeaa8fc9383b424cce128a890e07cb6025f3 | |
| ToppCell | COVID-19_Moderate-HSPC|World / disease group, cell group and cell class | 4.35e-04 | 184 | 36 | 3 | ccc93babe1fcdeb66b78e1d8414357877a7c45bd | |
| ToppCell | systemic_lupus_erythematosus-managed-Hematopoietic-progenitor_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.42e-04 | 185 | 36 | 3 | 2c07991e0907ded67e21ab2e66be21695842ed01 | |
| ToppCell | COVID-19_Moderate-HSPC|COVID-19_Moderate / disease group, cell group and cell class | 4.42e-04 | 185 | 36 | 3 | cacc6ab5f26f6c803894567fb838ea06eaa7efe5 | |
| ToppCell | LPS_only-Hematopoietic_Meg-Ery-Erythroid|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.49e-04 | 186 | 36 | 3 | affc246a1091e44dc85a5e237c778a7541d5a2b4 | |
| ToppCell | systemic_lupus_erythematosus-flare-Hematopoietic-progenitor_cell|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.49e-04 | 186 | 36 | 3 | ffd4510b4435d9bf94c2ef14c629f73ab78c5d93 | |
| ToppCell | LPS_only-Hematopoietic_Meg-Ery|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.49e-04 | 186 | 36 | 3 | 40d1e15402fdfb3b5ae850a2070cd4b68fda3159 | |
| ToppCell | LPS_only-Hematopoietic_Meg-Ery-Erythroid-Erythroid|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.49e-04 | 186 | 36 | 3 | e5014443e9d6e25943308483e20d48b776ae5373 | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 4.49e-04 | 186 | 36 | 3 | 03db813598b67b1e08f759758a1c2023396921fa | |
| ToppCell | systemic_lupus_erythematosus-flare-Hematopoietic-progenitor_cell-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.63e-04 | 188 | 36 | 3 | c613c6c7b6de8ed514253c9f9b8622c56fcc1452 | |
| ToppCell | hematopoetic_progenitors-CD34+_HSC|World / Lineage and Cell class | 4.70e-04 | 189 | 36 | 3 | 51ff31c9cf5eff98ad01c0455dc4ae4908713575 | |
| ToppCell | COVID-19_Severe-HSPC|World / disease group, cell group and cell class | 4.70e-04 | 189 | 36 | 3 | 555c0b13f1508b9e3712b36d77144e73e828bc76 | |
| ToppCell | Healthy-HSPC|Healthy / disease group, cell group and cell class | 4.70e-04 | 189 | 36 | 3 | 214b225effc40ca1b83dd8052f2a7b80b65d4938 | |
| ToppCell | (5)_Fibroblasts-(5)_Fibroblast-C_(Myofibroblast)|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4) | 4.78e-04 | 190 | 36 | 3 | 71e112dfb8c3190fe0286b45a046ea789eb6a8db | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.78e-04 | 190 | 36 | 3 | 7986586b7c82e91c71102cc8c4d7a689ae63ab4d | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 4.85e-04 | 191 | 36 | 3 | fa380a8752de158974b2ae5e741573439719cc0d | |
| ToppCell | ILEUM-non-inflamed|ILEUM / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 4.85e-04 | 191 | 36 | 3 | c4a78ef7b87ffadbb1b9b69cbfa7c164ca456f9a | |
| ToppCell | hematopoetic_progenitors-CD34+_MEP_2|hematopoetic_progenitors / Lineage and Cell class | 4.85e-04 | 191 | 36 | 3 | 3b061dbc10918be7cbbd4453311d2c1ebf18c6b2 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Endothelial-endothelial_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.92e-04 | 192 | 36 | 3 | 042391162df2e3d0027688dd14163c4c6821afe0 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Endothelial|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.92e-04 | 192 | 36 | 3 | 71b0bfee0461ff64cef35881db3959c517e9731b | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Endothelial-Endothelial_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.92e-04 | 192 | 36 | 3 | 9d53b42cdb537b30233cdfdc08052c8b13a1113f | |
| ToppCell | Influenza_Severe-RBC|Influenza_Severe / Disease group and Cell class | 4.92e-04 | 192 | 36 | 3 | f19b6da3fd98da1a76d2570137a8f73a3850ebcb | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.92e-04 | 192 | 36 | 3 | 5c7e8b80b44d9ce55c797cdf8267ac5382e26cac | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)-hematologic-hematopoietic_progenitor-hematopoietic_stem_cell|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.92e-04 | 192 | 36 | 3 | 61677831b096b36f6325e9cb047483dd72aa71c2 | |
| ToppCell | TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6|TCGA-Prostate / Sample_Type by Project: Shred V9 | 5.00e-04 | 193 | 36 | 3 | abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 5.08e-04 | 194 | 36 | 3 | a3e5a15cf6c1361207f661ee15eb634f77daf1cb | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 5.08e-04 | 194 | 36 | 3 | 71d3c7448b1734de54187f902f65649f9283bd4c | |
| ToppCell | Mild-NK|Mild / Disease group and Cell class | 5.15e-04 | 195 | 36 | 3 | be88a7507cd6a0a9dfe424312d9365039eef7b74 | |
| ToppCell | 367C-Fibroblasts-Fibroblast-C_(Myofibroblast)-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 5.23e-04 | 196 | 36 | 3 | 6730743cf088c419ccc2d28765769fc09d3ba6a7 | |
| ToppCell | 367C-Fibroblasts-Fibroblast-C_(Myofibroblast)|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 5.23e-04 | 196 | 36 | 3 | 21dab89f3699037138a9c7a0e4dc98739a9fad9c | |
| ToppCell | 10x5'v1-week_12-13-Hematopoietic-erythroid-mid_erythroid|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.31e-04 | 197 | 36 | 3 | d8f99a9f2367c8bc9308b0c64d0226875262927a | |
| ToppCell | ILEUM-inflamed-(7)_Endothelial_cell-(7)_CD36+_endothelial_cells|(7)_Endothelial_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 5.31e-04 | 197 | 36 | 3 | 66339b5aae3952f5c484c9dcb0cfb4fbd828d4cb | |
| ToppCell | VE-NK|VE / Condition, Cell_class and T cell subcluster | 5.31e-04 | 197 | 36 | 3 | cae6ff8763501e7a5897b50188ac2640d65a47c0 | |
| ToppCell | VE-NK-|VE / Condition, Cell_class and T cell subcluster | 5.31e-04 | 197 | 36 | 3 | ee89b8521fb4faaed9e4d39f7171e45eccf38b00 | |
| ToppCell | facs-Lung-18m|Lung / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.46e-04 | 199 | 36 | 3 | c11e0044d3cc37f6bb26df033ad4448b419addfc | |
| ToppCell | Tracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations | 5.46e-04 | 199 | 36 | 3 | 94b94b17ca18b8dc27b91da1f2ccf89e03cc7035 | |
| ToppCell | LPS_anti-TNF-Hematopoietic_Erythro-Megakary-Erythro-Mega|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 5.46e-04 | 199 | 36 | 3 | 284ee9632413f6404fc0b0c7c393ad813db834f2 | |
| ToppCell | TCGA-Stomach-Primary_Tumor|TCGA-Stomach / Sample_Type by Project: Shred V9 | 5.46e-04 | 199 | 36 | 3 | 38f1f612b29feb868322999ceeda78e52447ec4f | |
| ToppCell | LPS_anti-TNF-Hematopoietic_Erythro-Megakary|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 5.46e-04 | 199 | 36 | 3 | 6c174dbcc25b980f10a3d1dfe39e613acac73bb6 | |
| ToppCell | TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma|TCGA-Stomach / Sample_Type by Project: Shred V9 | 5.46e-04 | 199 | 36 | 3 | b10698aee2e6c17bc559eb4f723024141f914b90 | |
| ToppCell | (2)_B_cell-(21)_B_cell_IgG_Plasma|(2)_B_cell / shred on Cell_type and subtype | 5.55e-04 | 200 | 36 | 3 | 2831060d52b210f8927527810611735a99b61999 | |
| Disease | Microcephaly | 6.95e-05 | 67 | 35 | 3 | C0025958 | |
| Disease | prion disease | 2.31e-04 | 19 | 35 | 2 | EFO_0004720 | |
| Disease | serum IgG glycosylation measurement | 3.59e-04 | 523 | 35 | 5 | EFO_0005193 | |
| Disease | smoking status measurement | 3.65e-04 | 1160 | 35 | 7 | EFO_0006527 | |
| Disease | pallidum volume | 4.03e-04 | 25 | 35 | 2 | EFO_0006933 | |
| Disease | androsterone sulfate measurement | 7.05e-04 | 33 | 35 | 2 | EFO_0021117 | |
| Disease | Adenoma | 8.40e-04 | 36 | 35 | 2 | C0001430 | |
| Disease | Adenoma, Microcystic | 8.40e-04 | 36 | 35 | 2 | C0205648 | |
| Disease | Adenoma, Monomorphic | 8.40e-04 | 36 | 35 | 2 | C0205649 | |
| Disease | Adenoma, Basal Cell | 8.40e-04 | 36 | 35 | 2 | C0205646 | |
| Disease | Follicular adenoma | 8.40e-04 | 36 | 35 | 2 | C0205647 | |
| Disease | Papillary adenoma | 8.40e-04 | 36 | 35 | 2 | C0205650 | |
| Disease | Adenoma, Trabecular | 8.40e-04 | 36 | 35 | 2 | C0205651 | |
| Disease | complement factor H measurement | 1.09e-03 | 41 | 35 | 2 | EFO_0008097 | |
| Disease | executive function measurement, unipolar depression, cognitive function measurement | 1.68e-03 | 51 | 35 | 2 | EFO_0003761, EFO_0008354, EFO_0009332 | |
| Disease | nervous system disorder | 1.81e-03 | 53 | 35 | 2 | C0027765 | |
| Disease | mean reticulocyte volume | 2.38e-03 | 799 | 35 | 5 | EFO_0010701 | |
| Disease | attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement | 2.41e-03 | 801 | 35 | 5 | EFO_0003888, EFO_0007052, MONDO_0002491 | |
| Disease | Benign Neoplasm | 2.96e-03 | 68 | 35 | 2 | C0086692 | |
| Disease | Neoplasms | 2.96e-03 | 68 | 35 | 2 | C0027651 | |
| Disease | asthma, endometriosis | 3.50e-03 | 74 | 35 | 2 | EFO_0001065, MONDO_0004979 | |
| Disease | Epilepsy, Cryptogenic | 4.28e-03 | 82 | 35 | 2 | C0086237 | |
| Disease | Awakening Epilepsy | 4.28e-03 | 82 | 35 | 2 | C0751111 | |
| Disease | Aura | 4.28e-03 | 82 | 35 | 2 | C0236018 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| HNNNDAKQNHDLTHR | 166 | Q9BVC5 | |
| QQQQHHHHHHHQQQQ | 381 | Q4VCS5 | |
| HHHHHHQQQQQQQPQ | 386 | Q4VCS5 | |
| RRHPQHLHQQHHGDA | 1056 | Q9NR09 | |
| GLQHDESQHHQVPHR | 201 | Q8NEC5 | |
| LHCNLNEHNHHLIND | 241 | P56545 | |
| SGHHTHHQSDNNNEK | 451 | Q58WW2 | |
| VAPQQNALHHHHGNS | 591 | Q13627 | |
| SQQRQDPSHAEHHDH | 341 | Q8WXS8 | |
| DQQPGHQKNLHAHNH | 356 | Q9Y2G4 | |
| KRHRHRGQHHQQQQA | 261 | Q7L2J0 | |
| HTSHNKNDHLQEEDH | 111 | Q8NCR3 | |
| EAVQNDNHHASHGHH | 26 | P55316 | |
| QQHKLKTHQHHNPNE | 241 | Q32MH5 | |
| QSHPNVVNLHEVHHD | 461 | O75676 | |
| VKAHHHQHSHHPQQQ | 121 | Q9UBE8 | |
| DQSHLKHHQTPDPHQ | 6 | Q9BXL5 | |
| KHHQTPDPHQEENHS | 11 | Q9BXL5 | |
| HVAHLALKHRQGNNH | 576 | A2A3N6 | |
| AQNNNANIHDNNHHH | 501 | Q6PIJ6 | |
| ANIHDNNHHHPDDSD | 506 | Q6PIJ6 | |
| HHHHHQPEAEPRQEK | 216 | I3L3R5 | |
| HQHIQHHPNHQHQTL | 421 | Q9UPW0 | |
| DQRAGHQHQHHQPIC | 156 | A6NNE9 | |
| HPHFQHHHSQHQQQR | 236 | Q17RY0 | |
| HHHSQHQQQRRSPAS | 241 | Q17RY0 | |
| AVQEGKHFHSHNHQH | 116 | Q9ULF5 | |
| HNHQHSHNHLNSENQ | 126 | Q9ULF5 | |
| EQQHQHFHGAHLQAD | 21 | Q8TAU0 | |
| VCHNHHNHNSIGKQV | 1736 | Q01668 | |
| CEADDNHQQLHGHHN | 306 | Q5THK1 | |
| FQMQPQHQHQHQHQH | 311 | Q9H6I2 | |
| KNGERVHHHPHKTNN | 216 | Q969F9 | |
| NLHQHDPQDLRHNGN | 151 | P0DPB3 | |
| HHKHKGQHRQGHPEN | 246 | P49908 | |
| MQHHHQQHHQPELQQ | 996 | P55197 | |
| PHHHQQQQPQHAFNA | 36 | Q99967 | |
| QQQHQPQQQQHHHHH | 71 | P52655 | |
| QPHSQILHHHLQQDG | 1041 | Q14157 | |
| RSQHHHHHHQQQLQP | 6 | O95271 | |
| KPADPEEQQSHHHHH | 131 | Q9Y2X9 | |
| HQHVQQQPAQHHRDV | 181 | Q9Y2X9 | |
| RNHHNHPQNHLNQDI | 1586 | Q68DE3 | |
| EHAPHHIHDNNKNRN | 1841 | Q9Y4A5 |